Navigation Links
Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma: Phase I/II and Phase II Studies, ASCO 2009
Date:5/18/2009

SAN MARINO, Calif., May 18 /PRNewswire/ -- Epeius Biotechnologies (www.epeiusbiotech.com) today announced the results of two related studies using Rexin-G, a tumor-targeted anti-cancer agent designed to seek-out and destroy metastatic cancers that have spread throughout the body. While Rexin-G is currently approved for the treatment of all solid tumors in the Republic of the Philippines, Epeius Biotech is conducting a series of advanced Phase I/II studies and a Phase II confirmatory trial in the U.S. The Phase I/II study evaluating the safety and efficacy of Rexin-G in chemotherapy-resistant metastatic bone and soft tissue sarcomas (ASCO Annual Meeting 2009, #10513) demonstrated that Rexin-G was well-tolerated with no dose-limiting toxicity. Moreover, Rexin-G exhibited dose-dependent efficacy in terms of tumor control rates, progression-free survival, and overall survival, thus validating both the efficiency of the tumor-targeting technology and the pharmacological mechanisms of action.

The efficacy and safety of Rexin-G was further confirmed in a Phase II study for chemotherapy-resistant osteosarcoma. Again, in the absence of dose-limiting toxicity, Rexin-G was demonstrated to control tumor growth, prolong progression-free survival, and improve overall survival in osteosarcoma patients who have failed known therapies. It is important to note that these outstanding results, were achieved when Rexin-G was administered as monotherapy-unlike many other so-called targeted biologics where one or more toxic agents are used in combination in order to achieve even marginal results. Based on a critical analysis of its performance in the clinic, the U.S. FDA recently granted Rexin-G Orphan Drug Status for both soft tissue sarcoma and osteosarcoma. The results of these studies will be presented by Dr. Sant P. Chawla, Sarcoma Oncology Center, Santa Monica, CA, and discussed by Dr. Katherine Janeway, Dana-Farber Cancer Institute, Boston, MA on Saturday, May 30, 2009 at 5:00 p.m. EST/EDT.

About Epeius Biotechnologies

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its high-performance gene delivery systems that are embodied in Rexin-G and Reximmune-C, a tumor-targeted cancer vaccine. To learn more about ongoing clinical trials, please contact Dr. Erlinda M. Gordon at egordon@epeiusbiotech.com.

*(LOGO 72dpi: Send2Press.com/mediaboom/08-0421-Epeius_72dpi.jpg)

This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R). http://www.Send2Press.com


'/>"/>
SOURCE Epeius Biotechnologies
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. FDA Approves the Opening of a Phase II Registration Protocol Using REXIN-G(R) for Osteosarcoma in California U.S.A.
2. Lesson From the States: Lack of Cost Controls Derailed California Health Reform, Led to Budget Overruns and Unaffordable Policies in Massachusetts
3. China Shenghuo Announces Management Expansion and Enhanced Internal Controls
4. Enhanced skin cancer risk linked to defects in cellular aging controls
5. Best Practice Database Supports Chemistry, Manufacturing & Controls (CMC) Operations
6. Gems Sensors & Controls Introduces Highly Accurate FDA Compliant Flow Sensor
7. Molecular partnership controls daily rhythms, body metabolism
8. NIH scientists find a novel mechanism that controls the development of autoimmunity
9. Gladstone scientists identify single microRNA that controls blood vessel development
10. MicroRNA controls expression of oncogenes
11. Monkey Controls Robotic Arm With Brain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Medical Market Analysis 2016 - Forecast to 2022" report ... The report contains up to date financial data derived from ... of major trends with potential impact on the market during ... market segmentation which comprises of sub markets, regional and country ...
(Date:6/23/2016)... June 23, 2016 Bracket , a leading ... next generation clinical outcomes platform, Bracket eCOA (SM) 6.0, ... June 26 – 30, 2016 in Philadelphia ... Clinical Outcome Assessment product of its kind to fully integrate ... Bracket eCOA 6.0 is a flexible platform for electronic ...
(Date:6/23/2016)... -- Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... . ... ... ... Astellas is ...
Breaking Medicine Technology: